Juvelook and Juvelook Volume are US FDA and KFDA (MFDS)-approved autologous collagen boosters combining biodegradable PLA and hyaluronic acid (HA).
Discover their particle mechanisms, longevity, comparative differences with HA fillers and Sculptra, and essential clinical insights from a medical director.
Published | October 26, 2026 | Last Updated: October 26, 2026
Medical Reviewer | Dr. Yumin Lee at MeSOnBOM Clinic
Author Profile: [Link to Medical Staff Profile Page]
Juvelook and Juvelook Volume are autologous tissue-regenerating collagen boosters combining biodegradable polymer PLA (polylactide) and hyaluronic acid (HA) to restore skin elasticity, fine lines, enlarged pores, atrophic acne scars, and structural facial volume, approved by the Ministry of Food and Drug Safety (MFDS/KFDA) and the U.S. Food and Drug Administration (FDA).

Both formulations are engineered to degrade completely within the body over time without leaving synthetic residue, inducing natural structural remodeling.
Based on official Juvelook Product Guidelines and patented porous micro-particle architecture, the product is categorized into two distinct clinical formulations:
Juvelook (Skin Booster): Formulated with micro-particles measuring 10–30 µm, combining PLA and hyaluronic acid for intradermal injection to treat elasticity loss, superficial rhytids, pore dilatations, atrophic acne scars, and irregular skin texture.
Juvelook Volume: Formulated with larger micro-particles measuring 30–50 µm to deliver enhanced volumization and structural lifting.
It is targeted at deeper anatomical levels (the deep dermis and subcutaneous layer) to treat structural hollows, nasolabial folds, and volume deficiencies.
The primary mechanism relies on porous reticular micro-particles that sustain autologous neocollagenesis over an extended duration while minimizing the risk of nodule formation.

HA Hydration and Immediate Stabilization (Step 1):
Following injection, the non-crosslinked hyaluronic acid fraction binds interstitial moisture, delivering immediate hydration and soft structural support while facilitating uniform dispersion of PLA micro-particles.
Neocollagenesis via Porous Reticular Scaffolding (Step 2):
Host cells migrate into the micro-pores of the PLA particles, activating tissue fibroblasts.
This triggers the progressive synthesis of type I and type III collagen without provoking pathological foreign-body reactions.
Complete Biodegradation Without Residue (Step 3):
After stimulating localized collagen synthesis, the PLA micro-particles undergo hydrolytic cleavage, breaking down into water and carbon dioxide to be metabolized and excreted, leaving zero permanent foreign material behind.
The following matrix compares Juvelook formulations with crosslinked HA fillers, PLLA (Sculptra), and CaHA (Radiesse):
Parameter | Juvelook (Skin) | Juvelook Volume | Crosslinked HA Fillers | Sculptra (PLLA) | Radiesse (CaHA) |
|---|---|---|---|---|---|
Active Ingredients | PLA + Hyaluronic Acid | PLA (High Density) + HA | Crosslinked HA (BDDE) | Poly-L-lactic Acid (PLLA) | 30% CaHA + 70% CMC Gel |
Particle Size / Shape | 10–30 µm (Porous Reticular) | 30–50 µm (Porous Reticular) | Crosslinked Gel Matrix | 40–63 µm (Irregular Polygon) | 25–45 µm (Smooth Sphere) |
Primary Mechanism | Dermal ECM Restoration | Structural Volumization | Physical Hydrophilic Filling | L-Lactide Immune Response | CaHA Scaffold Stimulation |
Target Depth | Papillary to Reticular Dermis | Deep Dermis to Subcutaneous | Mid Dermis to Subcutaneous | Subcutaneous / Periosteal | Subdermal / Supraperiosteal |
Onset of Visible Results | 3–4 weeks | 4–6 weeks | Immediate (Day 0) | 6–8 weeks | Immediate (Gel) + 8–12 weeks |
Clinical Longevity | 12–16 months | 18–24 months | 6–12 months | Up to 24 months | 12–18 months |
Regulatory Clearance | KFDA / FDA Cleared | KFDA / FDA Cleared | MFDS / FDA Cleared | MFDS / FDA Cleared | MFDS / FDA Cleared |
Clinical injection procedures established in Hongdae follow a standardized four-step medical protocol (Consultation → Anesthesia → Injection → Post-Care):
Step 1 Consultation:
The patient's epidermal thickness, structural volume loss, depth of rhytids, and scar patterns are evaluated to determine the appropriate product type and volume (cc).
Step 2 Topical Anesthesia:
A high-concentration topical anesthetic cream is applied to the target area for 30–40 minutes to minimize procedural discomfort.
Step 3 Juvelook / Juvelook Volume Administration:
Juvelook: Administered intradermally via micro-droplet injection techniques to target fine wrinkles and enlarged pores uniformly.
Juvelook Volume: Delivered to deeper subcutaneous planes using a blunt safety cannula to treat hollow regions and deep folds.
Step 4 Post-Care Finishing:
Topical soothing and aseptic post-treatment care are applied to protect the barrier and prevent localized infection.
A1. On a visual analog scale (VAS) of 0 to 10, patient-reported discomfort averages between 2 and 3.
The application of topical lidocaine cream during Step 2, along with buffering agents incorporated during formulation preparation, ensures pain and tissue pressure remain minimal.
A2. While the hyaluronic acid carrier dissolves upon administration of hyaluronidase, the primary PLA micro-particles cannot be dissolved enzymatically.
However, Juvelook utilizes porous spherical micro-particles rather than irregular crystals, resulting in an exceptionally low incidence of nodule formation.
Proper pre-treatment hydration and correct plane delivery further safeguard against mechanical clumping.
A3. For 72 hours following treatment, patients must avoid high-temperature environments (such as saunas and steam rooms), strenuous exercise, and alcohol consumption to prevent vasodilation and excessive swelling.
Unlike conventional crystalline PLLA, aggressive post-treatment self-massage (such as the 5-5-5 protocol) is not required and should be avoided to prevent particle displacement; standard gentle cleansing, hydration, and sun protection are sufficient.

This column was written in compliance with medical regulations.
Individual results may vary, and temporary side effects such as bruising, swelling, or tenderness may occur; please consult with a qualified medical professional prior to treatment.
Author | Dr. Yumin Lee
Medical Institution | MeSOnBOM Clinic